The American Cancer Society stated that in 2014 about 237,000 women
and 2,200 men were diagnosed with breast cancer and nearly 465 men
and 41,211 women in the U.S. succumbed to breast cancer. Breast
cancer is the most common type of cancer, excluding non-melanoma skin
cancer, among women in the U.S. Predictive gene testing is also known
as presymptomatic testing. Considering the fact that this test is
completed even before the early signs of the disease or disorder are
yet to observed and thus enable determining person’s risk of
suffering disorder or disease. Predictive breast cancer gene testing
is done to identify the risk of developing the cancer in a person
having a family history of this disease. Earlier detection of breast
cancer helps to completely cure the patient and save the affected
breast. Since the advantages of early detection of breast cancer,
governmental and non-governmental organizations around the globe have
started taking initiatives to spread awareness regarding the disease
and early detection techniques available in their respective
territories. Increasing prevalence of breast cancer is a major
concern for governments that is encouraging them to conduct awareness
programs to reduce the mortality rate of caused by the disease.
Report Overview @
https://www.transparencymarketresearch.com/predictive-breast-cancer-gene-testing.html
Increasing incidence of breast cancer globally and initiatives taken
by governmental organizations to reduce morbidity rate caused by
breast cancer are factors driving the predictive breast cancer
genetic testing market. However, acquisition of small market entrants
by leading market players, high initial capital investments, and
strict government regulations for predictive breast cancer genetic
tests restrain the predictive breast cancer gene testing market.
The global predictive breast cancer genetic testing market can be
segmented into patient type, end-user, and geography. Based on
patient types, the predictive breast cancer genetic testing market
can be divided into family history, age group, and gender. Family
history is taken into consideration due to people having breast
cancer in their family are at higher risk of developing breast
cancer.
According to the American Cancer Society, around 13% patients
diagnosed with breast cancer have a family history of this disease.
According to a survey conducted by the University of North Carolina,
around seven percent women are diagnosed with breast cancer under the
age of 40. Prevalence of breast cancer is higher in women who are in
age group between 40 and 55. Being a women is the strongest risk
factor for breast cancer, though rare men also are risk of breast
cancer. According to the Canadian Cancer Society, in 2015 around 220
men were diagnosed with breast cancer in Canada. In terms of end
user, the predictive breast cancer genetic testing market is
segmented into clinical laboratories, cancer hospitals, research
laboratories.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1789
Based on geography, the predictive breast cancer gene testing market
can be segmented into North America, Europe, Asia Pacific, and Rest
of the World. North America dominates the predictive breast cancer
gene testing market followed by Europe. Growing awareness regarding
breast cancer among the adult population and availability of
sophisticated technologically and advanced treatment options are
factors propelling the market in these regions. According to the
Canadian Cancer Society, approximately 1,175 new breast cancer cases
are likely to be diagnosed in women under the age of 40, representing
nearly 5% of all new breast cancers and nearly 3,300 new cases of
breast cancer are expected to be diagnosed in women between the ages
of 40 and 49, representing about 13% of all new breast cancers in
2017. Asia Pacific is one of the most promising regions for the
predictive breast cancer gene testing market as the region is
developing rapidly. Emerging economies and easy market penetration in
developing countries in Asia are projected to drive the predictive
breast cancer gene testing market in the near future.
Key players operating in the predictive breast cancer gene testing
market are Myriad Genetics, Inc., Complete Genomics Incorporated,
Ambry Genetics, PreventionGenetics, and Illumina, Inc.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=1789<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment